Squamous cell carcinoma of head and neck
RecruitingStudy of Cetuximab and Paclitaxel for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Pembrolizumab Treatment
Study of Cetuximab and Paclitaxel for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Pembrolizumab Treatment
- Disease:Squamous cell carcinoma of head and neck
- Substances:CetuximabPaclitaxel
Spain- Participants:18–64 years · 65+ years
- Substances:Cetuximab
- Sponsor:Grupo Espanol De Tratamiento De Tumores De Cabeza Y Cuello








